BCG
DNLI icon

Breakwater Capital Group’s Denali Therapeutics DNLI Stock Holding History

Breakwater Capital Group’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$401K Buy
15,601
+15
+0.1% +$308 0.05% 272
2026
Q1 		$299K Sell
15,586
-780
-5% -$15.5K 0.04% 306
2025
Q4 		$270K Buy
16,366
+500
+3% +$8.44K 0.04% 302
2025
Q3 		$230K Sell
15,866
-1,230
-7% -$17.7K 0.03% 324
2025
Q2 		$239K Buy
17,096
+2,081
+14% +$29.3K 0.04% 311
2025
Q1 		$204K Buy
+15,015
New +$288K 0.04% 320
2024
Q4 		– Sell
-7,642
Closed -$223K – 289
2024
Q3 		$223K Buy
+7,642
New +$189K 0.04% 269

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Breakwater Capital Group's DNLI Position: Q2 2026 in Review

Breakwater Capital Group increased its Denali Therapeutics (DNLI) stake by 0.1% in Q2 2026, buying an estimated $308 and bringing the position to 15,601 shares worth $401K. The position accounts for 0.05% of the portfolio, ranked #272.

Breakwater Capital Group first reported a position in DNLI in Q3 2024 and has held it in 7 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Breakwater Capital Group held 15,601 shares of Denali Therapeutics worth $401K as of Q2 2026.
  • Breakwater Capital Group bought 15 Denali Therapeutics shares in Q2 2026, an estimated $308.
  • Denali Therapeutics made up 0.05% of Breakwater Capital Group's portfolio in Q2 2026, its #272 holding.
  • Breakwater Capital Group first reported a position in Denali Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Breakwater Capital Group's 13F filing for Q2 2026, filed 8 Jul 2026.